Exozymes price to book ratio EXOZ
Market value divided by the book value of the company's net assets, since 2025.
- Today, Nov 2, 2026
- 11.5×
- Peer median
- 1.8×
Exozymes' price to book ratio is 11.5× as of Nov 2, 2026.
The median for 10 healthcare stocks of a similar size is 1.8×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 11.5× | 10.2× | 55.0× |
| 2025 | 17.9× | 8.0× | 25.0× |
Against its peers
Companies in Healthcare nearest Exozymes' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| EXOZExozymes | 11.5× |
| ATNMActinium Pharmaceuticals | 1.5× |
| NEPHNephros | 2.9× |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.4× |
| LFVNLifevantage | 2.2× |
| ICCCImmucell | 3.1× |
| KEQUKewaunee Scientific | 1.3× |
| PDEXPro DEX | 3.7× |
| PLXProtalix BioTherapeutics | 2.9× |
| NATRNatures Sunshine Products | 1.2× |
| Peer median | 1.8× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Exozymes
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.